Navigation Links
Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
Date:8/29/2012

ternational clinical trial programs in COPD comprising 10 studies in total with more than 7,000 patients across 42 countries[1-5,13-20]. The first five studies (ILLUMINATE, SHINE, BRIGHT, ENLIGHTEN, SPARK) have already completed in 2012 with three additional studies (BLAZE, ARISE, BEACON) expected to complete by the end of the year. The studies are designed to investigate efficacy, safety and tolerability, exercise endurance, exacerbations, breathlessness and quality of life[1-5,13-17].

CEO of Sosei, Shinichi Tamura commented:

"The SPARK study demonstrated a meaningful reduction in exacerbations in COPD patients; something that is of major benefit for patients and doctors and eases the burden of healthcare costs. We look forward to more detailed data from both glycopyrronium bromide (NVA237) and QVA149 at the upcoming European Respiratory Society meeting in Vienna in early September with the first filings for QVA149 expected in Europe and Japan by the end of this year."

Notes for editors

About NVA237/QVA149

NVA237 (glycopyrronium bromide - Seebri® Breezhaler®) was licensed to Novartis in April 2005 by Sosei and its co-development partner, Vectura. It is an investigational LAMA developed as a once-daily inhaled maintenance therapy for the treatment of COPD. Phase III data from the GLOW1, 2 and 3 studies demonstrated that glycopyrronium bromide increased patients' lung function over a 24-hour period compared to placebo with a fast onset of action at first dose, and improved exercise endurance versus placebo[21-23].

QVA149 is an investigational inhaled, once-daily, fixed-dose combination of NVA237 and the LABA, indacaterol maleate, for which Novartis received European regulatory approval as Onbrez® B
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
4. BioNeutral Group Receives $400,000 in Equity Financing
5. MiMedx Group Completes $5,000,000 Private Placement
6. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
7. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
8. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
9. Statewide Network of Angel Investor Groups Announced in Alabama
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
11. Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Md. , June 19, 2013 Synthetic Biologics, ... the prevention and treatment of serious infectious diseases, announced today ... 6 th Annual OneMedForum New York Conference on Thursday, ... New York City . Mr. Riley is scheduled to ... webcast of Synthetic Biologics, presentation can be accessed by logging ...
(Date:6/19/2013)... Bayer CropScience will honor Illinois beekeeper ... Community Leadership Award. The award will be announced at ... Washington, D.C., an event where supporters of pollinator health ... supply. , The Bayer Bee Care Community Leadership ... the honey bee colony to benefit their community. Applicants ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 BioConvergence ... the speaking faculty at 2013’s BioLogistics Summit in ... conference, coordinated by Cold Chain IQ and IQPC, ... This “complexity” is, in part, attributed to current ... , “Implicit within these trends is an increase ...
(Date:6/19/2013)... MN (PRWEB) June 19, 2013 Express ... abuse tests, today announced that it has received Class ... market and sell its DrugCheck® NxStep Onsite Drug ... use of the rapid screening device in near-patient settings, ... Drug Screen Cup received Health Canada Class III approval ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... the U.S. Department of Energy,s Argonne National Laboratory, will ... 138 on Nanoalloys: From Theory to Application, to be ... in the United Kingdom. , The Faraday Discussions are ... have been of enormous influence in reviewing the current ...
... Stevens Institute of Technology and NACE International, ... Section, will host the Winter 2007 Corrosion Symposium: ... Charles V. Schaefer, Jr. School of Engineering & ... Keith Sheppard, a professor materials engineering, will welcome ...
... splinting and bracing technology, ST. PAUL, ... of St. Paul, Minn., and Product Innovations, ... announce the launch of Exos Corporation, a ... innovative orthopedic,support devices. Exos will focus ...
Cached Biology Technology:Enova Medical Launches Exos Corporation 2
(Date:6/19/2013)... specifically for human consumption qualifies as a gluten-free cereal ... (CD), scientists have confirmed in a study published in ... , Joyce Irene Boye and colleagues point out ... States alone have CD. They develop gastrointestinal and other ... that contain gluten-related proteins. Boye,s team sought to expand ...
(Date:6/19/2013)... ITHACA, N.Y. A Cornell University study offers further ... 4 million to 6 million years ago was profoundly ... in turning genes on and off. , The study, ... evidence for a 40-year-old hypothesis that regulation of genes ... is little difference between humans and chimps in the ...
(Date:6/19/2013)... world-leading provider of scientific, technical and medical information products ... a new open access journal, GeoResJ . ... earth and planetary science journals portfolio has its first ... a forum for rapid publication of top research within ... co-edited by six Executive Editors, each covering a different ...
Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... by the journal Nature until January 30, 1 PM Eastern ... Research Institute have identified a pathway in the brain that ... The findings suggest a new target for anti-smoking therapies. ... issue of the journal Nature . In the ...
... University of California, San Diego School of Medicine ... cognitive defects associated with a rare childhood neurological ... to be defective in LND are known to ... Alzheimer,s and Parknson,s diseases, suggesting common causes of ...
... statistically significant level to their sons, and the same is ... it does not seem to impact on the probability of ... not affect his daughter", Loureiro, a researcher at the Universidade ... the study, tells SINC. The research, which has been ...
Cached Biology News:Scripps Research scientists reveal key mechanism governing nicotine addiction 2Scripps Research scientists reveal key mechanism governing nicotine addiction 3Genetic clues to compulsive, self-injurious behavior in rare childhood disorder 2Genetic clues to compulsive, self-injurious behavior in rare childhood disorder 3Smoking habits are transmitted from mother to daughter and father to son 2
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
... BIP-NC H-IPMIK-OH ... PROTECT FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT ... Bax-Inhibiting Peptide, V5 (Cat. No. 196810) that ... suppress Bax-mediated apoptosis (~200 μM). Purity: ...
Biology Products: